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The efficacy of conventional anti-tumour therapies is limited by
several physical and physiological barriers (Jain, 1998). In addi-
tion, acquired resistance to chemotherapeutic drugs poses a major
challenge to cancer therapy. Therefore, alternate strategies for
cancer treatment are sought. Tumour growth beyond 1–2 mm in
diameter requires the formation of new blood vessels from pre-
existing vasculature, a process also called tumour angiogenesis
(Folkman, 1992). Tumour angiogenesis is a complex process
involving matrix degradation, endothelial cell (EC) proliferation,
EC migration and tube formation. Positive and negative regulators
control each step in angiogenesis. However, it is the eventual
balancing act of these mediators that control the final angiogenic
response (Iruela-Arispe and Dvorak, 1997).
Vascular endothelial growth factor (VEGF) has been considered
as one of the most important positive regulators of tumour angio-
genesis (Neufeld et al, 1999). VEGF belongs to the family of
cystine knot proteins, which includes P1GF, VEGF-B, VEGF-C,
VEGF-D and VEGF-E (Veikkola and Alitalo, 1999). VEGF is
secreted as a disulphide-linked dimeric glycoprotein with five
different isoforms (VEGF206, 189, 165, 145 and 121) being
produced by means of alternate splicing (Neufeld et al, 1999).
Three types of VEGF receptors have been identified, flt-1
(VEGFR-1), KDR/flk-1 (VEGFR-2) and flt-4 (VEGFR-3)
(Neufeld et al, 1999). All three receptors consist of seven IgG-like
domains, a transmembrane sequence and an intracellular kinase
domain. VEGF binds preferentially VEGFR-1 and VEGFR-2,
whereas VEGFR-3 interacts with VEGF-C and VEGF-D. More
recently, an isoform-specific VEGF receptor was identified on
endothelial and tumour cells, neuropilin-1 (NP-1), to which
VEGF165 binds to via its exon 7 encoded heparin-binding domain
(Soker et al, 1996; 1997). NP-1 has been previously associated
with signaling axon guidance during neural development.
However, new information shows that NP-1 enhances the mito-
genic effects of VEGFR-2 signaling events in endothelial cells
(Soker et al, 1998).
Receptors for VEGF (VEGFR-1 and VEGFR-2) with the excep-
tion of the newly identified NP-1, are expressed almost exclu-
sively by endothelial cells and they are markedly over-expressed
in the stromal vessels supplying tumours (Plate et al, 1993).
Normal quiescent blood vessels show negligible levels of
VEGFR-1 and VEGFR-2. Moreover, tumour-associated vascular
endothelium proliferates at a faster rate than the normally quies-
cent endothelium (Baillie et al, 1995) and is therefore vulnerable
to anti-proliferative endothelial cell-targeted therapy (Denekamp,
1982). As a consequence, selective destruction of tumour blood
vessels results in histologically apparent thrombosis or haemor-
rhaged necrosis of the tumour (Burrows and Thorpe, 1993).
We have previously reported that a toxin polypeptide linked to
the VEGF165 isoform can be used to target VEGF receptors and
inhibit the proliferation of endothelial cells (Ramakrishnan et al,
1996). Furthermore, the VEGF165–toxin conjugate was able to
inhibit angiogenesis in the chick chorioallantoic membrane assay.
More importantly, VEGF165–toxin treatment leads to the inhibi-
tion of ovarian cancer growth in an experimental tumour model
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doi: 10.1054/ bjoc.2000.1439, available online at http://www.idealibrary.com on (Olson et al, 1997). VEGF121 differs from all the other higher
molecular weight species by the absence of the heparin-binding
domain encoded by exon 7. VEGF121 binds preferentially to
VEGFR-2 (Gitay-Goren et al, 1996) and does not bind to the NP-1
receptor, which is also expressed in adult heart and placenta. As a
consequence, we were interested in testing whether the VEGF121
isoform could be used to prepare cytotoxic conjugates specific for
endothelial cells. A truncated form of diphtheria toxin (DT385)
was employed as the effector molecule. DT385 contains the
catalytic domain and the translocation domain of diphtheria toxin
but lacks the innate receptor-binding domain. DT385 was further
genetically modified to incorporate a cysteine residue at the
carboxyl terminus to facilitate chemical conjugation. DT385
catalytically ADP-ribosylates a unique histidine residue (diph-
thamide) of elongation factor-2, resulting in irreversible inhibition
of protein synthesis. The present study shows that recombinant
VEGF121 linked to DT385 efficiently inhibited endothelial
cell proliferation and angiogenesis. More interestingly, the
VEGF121–DT385 conjugate was selectively cytotoxic to prolifer-
ating endothelial cells and did not affect the viability of confluent
cultures. Finally, the conjugate effectively inhibited the growth of
tumours in vivo and specifically targeted tumour blood vessels
without apparent toxicity. In summary, this study provides
evidence that VEGF121-mediated toxin delivery differentially
affects the proliferating endothelium. Moreover, we show that
VEGF121–toxin conjugates can function as anti-angiogenic
tumour therapies bypassing potential NP-1-mediated toxicity
issues.
MATERIALS AND METHODS
Culture conditions for HUVEC have been described
(Ramakrishnan et al, 1996). Endothelial cells were used within the
first six in vitro passages. The yeast expression system (Pichia
pastoris) was purchased from Invitrogen (San Diego CA USA).
The rat glioma cell line C6 (ATCC, Rockville MD, USA) and the
human ovarian carcinoma cell line MA148 (University of
Minnesota, USA) were maintained in RPMI-1640 medium (Life
Technologies, Grand Island NY, USA) supplemented with 10%
foetal bovine serum and antibiotics (penicillin and streptomycin,
Life Technologies). Cultures were split twice a week at a ratio
of 1:3.
Expression and purification of VEGF121 and DT385
Cloning, expression and purification of VEGF121 have been
previously described (Mohanraj et al, 1995). The diphtheria toxin
polypeptide used in the present study was mutagenized by DNA-
PCR to include a free cysteine residue at the carboxyl terminus of
the truncated diphtheria toxin (DT385, residues 1–385 of the intact
toxin molecule) to facilitate chemical conjugation. Expression and
purification of the toxin polypeptide was performed as previously
described (Mohanraj et al, 1996).
Preparation and purification of VEGF121-toxin
conjugate
Purified VEGF121 was chemically conjugated to DT385 with the
heterobifunctional crosslinker N-succinimidyl-3-(2-pyridyldithio)
propionate (SPDP; Pierce Chemical, Rockford IL, USA) as
previously described (Ramakrishnan et al, 1996). VEGF121–toxin
conjugate was subsequently purified using a Ni-NTA affinity
column followed by size separation chromatography (Superdex-
75; Amersham Pharmacia Biotech, Piscataway NJ, USA). A
detailed description of the purification as been described
previously (Ramakrishnan et al, 1996).
Cytotoxicity assay
A detailed protocol on the cytotoxicity assay has been previously
described (Ramakrishnan et al, 1996). For measuring inhibition of
protein synthesis, VEGF–toxin treated cultures (48 h) were pre-
incubated in leucine free medium for 30 min and then pulsed with
1 µ Ci of [3H]leucine for 2 h. Radioactivity associated with the
cells was determined after lysing the cells in 100 µ l of 1.5 M
sodium hydroxide. The radioactivity associated with control
samples was considered as 100%. For measuring the sensitivity of
proliferating vs quiescent HUVEC cultures, the VEGF121–toxin
conjugate was added to cells on the 1st, 2nd, 3rd and 4th day after
seeding. For each day, separate sets of control cultures were used.
On day 4, control wells showed a 3-fold increase in [3H]leucine
incorporation when compared to day 1 control cultures.
Chick chorioallantoic membrane (CAM) assay
A modified CAM assay was carried out to investigate tumour cell-
induced angiogenesis (Gho et al, 1997). Here, exponentially
growing MA148 cells were resuspended at 2 × 107 cells ml–1 in
serum-free medium, which contained 150 mg ml–1 GELFOAM
(absorbable gelatin powder; Upjohn, Kalamazoo MI, USA) in the
absence or presence of VEGF121–DT385 toxin conjugate. 50 µ l
of the mixture was dispensed onto sterile plastic coverslips (Nalge
Nunc International, Naperville IL, USA) and allowed to form a
gel. The discs were then applied to the CAMs of 10-day-old
embryos. After 72 h of incubation, CAMs were observed and
photographed. Angiogenesis was assessed morphologically.
Mouse matrigel assay
MA148 cells were resuspended at 2 × 107 cells ml–1 in 10 mg ml–1
Matrigel solution (Collaborative Biomedical Products; Becton
Dickinson, Bedford MA, USA). 300 µ l of the mixture was then
injected subcutaneously into the right flank of 10-week-old female
athymic nude mice (Harlan Sprague Dawley, Indianapolis IN,
USA). Treatment was given daily by intraperitoneal injections of
30 µ g VEGF121–DT385 conjugate or PBS in case of the control
animals. Injections were administered for a 6-day period. Animals
were sacrificed on day 7. Next, matrigels were removed surgically
and subsequently observed for invasion of blood vessels into 
the matrix. The skin flaps associated with the matrigel were
photographed and examined for blood-vessel density.
Tumour growth inhibition studies
C6 rat glioma cells (ATCC, Rockville MD, USA) were resus-
pended at 2 × 107 cells ml–1 in serum-free RPMI 1640 medium.
100 µ l of the suspension was then injected subcutaneously into the
flanks of 6–8-week-old athymic, nu/nu mice (Harlan Sprague
Dawley). After allowing the tumour to establish (7 days), the
animals were randomized and treatment was initiated. The mice
were treated with daily intraperitoneal injections of 10 µ g
VEGF121–DT385 conjugate or equal amount of sterile saline for
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monitored by caliper measurements. Tumour volume was
calculated by the following formula:
Tumour volume (mm3) = a × b2 ×π /6
where a = length (longer diameter) and b = width (shorter
diameter).
Statistical significance between control and treated groups was
determined by the Student’s t-test. The experiment was repeated
twice with at least six animals per group. Control tumours and
residual tumours from treated animals were surgically removed at
the end of the experiment and processed for immunohistochemical
analysis.
The care and treatment of animals were in accordance with the
University of Minnesota Institutional Animal Care and Use
Committee (IACUC).
Immunohistochemical studies
Tumour tissues were surgically removed and fixed with 10%
buffered formalin (Sigma, St. Louis MO, USA). Paraffin
embedded tissue sections were prepared and processed for
immunohistochemical analysis. Sections were stained for endo-
thelial cells with rabbit anti-human Factor VIII antibody (von
Willebrand’s factor; Dako Corp, Carpenteria CA, USA, 1:250
dilution). Sections were developed with ABC kit (Vecta,
Burlingame CA, USA) and counterstained with haematoxylin
(Sigma). Tumour-cell apoptosis was analysed by TUNEL assay
(Boehringer Mannheim, Germany) and subsequently quantified
using digital images captured with an OLYMPUS fluorescent
microscope equipped with a CCD camera. The apoptotic index
was estimated by counting the number of TUNEL-positive pixels
per field using NIH Image analysis software (NIH, Bethesda MD,
USA).
RESULTS
The VEGF121–DT385 conjugate was purified by Nickel affinity
and gel filtration chromatography. SDS-PAGE analysis was used
to assess the purity of the conjugate (data not shown). We next
tested the effect of conjugate treatment on endothelial cells.
HUVEC cultures were treated with varying concentrations of the
construct. After 48 h of incubation with VEGF121–DT385, cell
viability was determined by measuring either protein or DNA
synthesis. Cultures treated with the conjugate showed a pro-
gressive decrease in viability with increasing concentrations of
conjugate. The addition of 100 nM conjugate almost completely
inhibited protein synthesis in HUVECs (Figure 1A) and 50% inhi-
bition was seen at 30 nM. DNA synthesis studies showed 50%
inhibition at 50 nM concentration (data not shown). For compara-
tive purpose a conjugate containing the VEGF165 isoform, which
can interact with NP-1 receptors, was also used. Both conjugates
showed very similar inhibition of protein synthesis (Figure 1A) as
well as DNA synthesis (data not shown) in HUVEC. Whereas,
equimolar concentrations of free DT385 showed no inhibitory
effect (data not shown) illustrating the specific targeting of the
toxin moiety via the VEGF isoforms. These results clearly demon-
strate that targeting VEGFR-2 with a VEGF121–DT385 conjugate
can efficiently inhibit protein synthesis and endothelial cell
viability in vitro.
To determine whether quiescent and proliferating endothelial
cells are equally sensitive to conjugate treatment we performed the
following experiment. Here, we treated HUVEC cultures on
different days after initial seeding. The HUVEC culture doubling-
time is approximately 18–24 h. Therefore, cultures become
subconfluent by day 2, confluent by day 3 and turn into quiescent
cultures by day 4 after seeding. Protein synthesis was used to
assess the effect of the conjugate since DNA synthesis decreases
as cultures become confluent. In contrast, protein synthesis in day
4 cultures was 3-fold higher when compared to day 1 control
wells. Therefore, protein synthesis is a good indicator of cell
viability in this type of experiment. Each time-point included its
own control samples to which treatment groups were compared.
Interestingly, only proliferating and subconfluent cultures were
sensitive for VEGF121–DT385. As illustrated in Figure 1B,
Inhibition of tumour angiogenesis 1079
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Figure 1 (A) The cytotoxicity of VEGF121–DT385 toxin conjugate on
human umbilical vein endothelial cells (HUVECs) was measured by
[3H]leucine incorporation. Each value is a mean of triplicate cultures from a
representative experiment and error bars show standard deviation.
   = VEGF165–DT385 conjugate.   VEGF121–DT385 conjugate. Conjugate
concentration 1 nM = 70 ng ml–1. (B) The selective inhibition of protein
synthesis was measured in proliferating vs confluent HUVEC cultures by the
VEGF121–DT385 conjugate. Conjugate was added to HUVEC cultures on
day 1, 2, 3 and 4 after initial seeding of cells. Two days later, cultures were
pulsed with 1 µ Ci of [3H]leucine. Each value is a mean of triplicate cultures
from a representative experiment and error bars show standard deviation.
   = Day 1;   = Day 2;    = Day 3;   = Day 4100 nM conjugate inhibited [3H]leucine incorporation in prolifer-
ating cells (day 1) by 95%. Similar concentrations of conjugate
showed a progressively decreasing level of cytotoxicity when
added to 2, 3 and 4-day old cultures. On day 2, when cultures were
subconfluent, 100 nM VEGF121–DT385 conjugate inhibited
protein synthesis by 66%. Three-day old confluent cultures were
still less sensitive to the conjugate (38% inhibition) whereas 4-day
old quiescent cultures were totally resistant to the construct.
Reduced sensitivity of confluent cultures is not due to a decrease
in protein synthesis. In fact, confluent cultures are highly active
and showed approximately 3-fold higher levels of [3H]leucine
incorporation per well due to increased cell density (data not
shown). Therefore, our results suggest that VEGF121–DT385
conjugate may also selectively inhibit proliferating endothelial
cells in areas of active angiogenesis.
Two independent assay systems were employed to test the anti-
angiogenic activity of the conjugate, the chick chorioallantoic
membrane (CAM) assay and a nude mouse matrigel assay. In the
CAM assay, MA148 cells were embedded in GELFOAM gelatin
powder and loaded onto the CAMs of 10-day-old embryos. The
incorporation of tumour cells into the gelatin matrix represented
an effective angiogenic stimulus, as indicated by a visible increase
in blood-vessel branch points. In contrast, control discs without
tumour cells did not induce neovascularization (data not shown).
When we included 1–3 µ g VEGF121–DT385 toxin conjugate per
disc, a potent inhibition of tumour cell-induced angiogenesis was
recorded (Figure 2B). In fact, at the described concentration, a
complete restraint of blood-vessel branching was observed. Free
DT385 toxin at equimolar concentrations did not affect tumour
cell-induced growth of blood vessels (data not shown) and results
were comparable to PBS treated CAMs (Figure 2A). Established
parent vessels were not affected by the conjugate, suggesting that
normal tissue vasculature is not affected by the VEGF121–DT385
construct.
In the nude mouse matrigel assay, similar results were obtained
with conjugate treatment. Tumour cells were incorporated into the
matrigel matrix and the mixture was injected subcutaneously into
the right flank of athymic nude mice. The matrigels were excised
on day 7 and examined for blood vessels. PBS-treated animals
showed extensive vascularization of the matrigel (Figure 2E). The
skin flaps that were associated with the matrigel also displayed a
high degree of blood-vessel density (Figure 2C). In contrast,
VEGF121–DT385 conjugate treatment effectively prevented the
invasion of blood vessels into the matrix. Excised matrigels of
conjugate-treated mice appeared literally avascular (Figure 2F).
Similarly, skin flaps associated with the matrigel revealed a clear
inhibition of angiogenesis (Figure 2D). These experiments demon-
strate that VEGF121 can effectively target toxin polypeptides to
endothelial cells in vivo and that these toxin conjugates function as
potent inhibitors of angiogenesis. VEGF121–DT385 toxin
constructs did not affect the in vitro growth rate of the angiogen-
esis-inducing tumour cell line MA148 (data not shown).
Therefore, the anti-angiogenic properties of the conjugate are due
to its endothelial cell-specific action and not because of direct
cytotoxic effects toward the tumour cells. Moreover, the phenom-
enon that established parent vessels were not affected by conjugate
treatment supports the previous observation that quiescent
endothelial cells are resistant to this construct.
Finally, VEGF–toxin conjugate was evaluated for its antitumour
activity in a mouse model system. Here, athymic nude mice were
transplanted with rat glioma cells (C6) and tumours were allowed
to establish for 7 days. Considering that the maximum inhibitory
activity in vitro was seen at 100 nM (7 µ g ml–1 conjugate) we esti-
mated a daily dose of 10 µ g VEGF121–DT385 conjugate per
mouse for the in vivo study (the average blood volume of a 20 g
mouse is approximately 1.6 ml). Conjugate was administered
intraperitoneally every day for a period of 14 days. Tumour
growth was monitored by caliper measurements. Data in Figure 3
show that conjugate treatment significantly inhibited the growth of
tumours (P < 0.01). The smaller tumour size directly correlated
with changes in the vasculature of the tumours in treated animals.
A representative photomicrograph of Factor VIII staining, an
endothelial cell-specific marker, is shown in Figure 4. A qualita-
tive analysis revealed that compared to control tumours (Figure
4A), the conjugate-treated tumours had a lower number of vessels
per field (Figure 4B). This result correlates well with a previous
study, where VEGF165–DT385 conjugate treatment significantly
reduced the microvessel density of a tumour as determined by
computer assisted image analysis (Wild et al, 2000). Moreover,
these studies revealed that conjugate treatment significantly
reduces the vessel length, vessel number and branch points in
1080 R Wild et al
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Figure 2 Inhibition of tumour cell-induced angiogenesis by
VEGF121–DT385. New blood-vessel growth was initiated by MA148, human
epithelial ovarian carcinoma cells as described in ‘Materials and methods’.
Two independent angiogenesis assays (CAM assay and mouse matrigel
assay) were used. (A and B) CAM assay, (A) control CAM (PBS-treated), 
(B) VEGF121–DT385 conjugate-treated CAM (3 µ g disc–1), (C–F) mouse
matrigel assay, (C) skin flap of a control animal (PBS-treated),
(D) representative skin flap of a VEGF121–DT385 conjugate-treated animal,
(E) control (PBS) matrigel, (F) conjugate-treated matrigel (A–D scale
bar = 1.5 mm; E, F scale bar = 2 mm)tumour samples. Here, tumours from treated animals showed
vascular damage and thrombotic lesions as revealed by the
extravascular deposition of Factor VIII (Figure 4B). As a conse-
quence, a large number of tumour cells, surrounding the damaged
vessels, showed pyknotic nuclei and other characteristics of dead
cells. Necrotic areas were evident up to 50–100 µ m away from the
damaged blood vessel, indicating that vascular targeting results in
broad tumour cell death even in distant regions from the blood
vessel.
This was further confirmed in TUNEL assays to detect apop-
totic cells from these tumours. Control tumours showed very low
numbers of TUNEL-positive cells (Figure 4C). In contrast, conju-
gate-treated tumours showed a large amount of apoptosis (Figure
4D). In fact, VEGF121–DT385 treatment resulted in an 8–9-fold
increase in apoptotic index (P < 0.008, Figure 4E). More interest-
ingly, apoptotic cells were increasingly found in the vicinity of
tumour vessels in conjugate-treated animals.
DISCUSSION
Both bacterial and plant toxins have been used to prepare tumour
cell-specific cytotoxic conjugates (Ramakrishnan et al, 1992).
However, their delivery to solid tumours in vivo is limited due to a
number of physical and physiological barriers (Jain, 1998).
Therefore, targeting the tumour-associated vasculature instead of
the tumour cells is advantageous. Tumour growth is dependent on
the establishment of new blood vessels. Endothelial cells present
in tumours exhibit many structural and biological differences
when compared to normal tissues. For instance, endothelial cells in
tumours proliferate actively (Denekamp, 1982; Baillie et al, 1995)
and overexpress endoglin and VEGF receptors (Plate et al, 1993;
Burrows et al, 1995). Consequently, toxin polypeptides can be
targeted to these moieties by either the ligand or an antibody
capable of binding to these receptors (Burrows & Thorpe, 1993;
Ramakrishnan et al, 1996; Olson et al, 1997; Seon et al, 1997).
We previously showed that VEGF165–toxin conjugates effi-
ciently inhibit tumour growth in vivo (Olson et al, 1997).
VEGF165–toxin treatment resulted in vascular damage at the
tumour without any apparent toxicity to normal tissues. Moreover,
the antitumour activity of the conjugate was strictly associated
with the anti-angiogenic properties of the construct, since the
employed experimental tumour cell line did not express VEGF
receptors. In contrast, a fusion toxin containing VEGF was found
to be cytotoxic to Kaposi’s sarcoma (KS) cell lines in vitro and in
vivo (Arora et al, 1999). However, KS cells used in this report
were positive for the VEGF receptors. Therefore, the observed
antitumour activity is due to both direct and indirect effects of the
fusion protein.
The biological activity of VEGF165 can be modulated by the
heparin-binding domain, which is encoded by exon 7. Through
this region, VEGF165 can also interact with NP-1. The VEGF121
isoform lacks this domain and therefore does not bind to NP-1. In
Inhibition of tumour angiogenesis 1081
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Figure 3 Antitumour activity of VEGF121–DT385 conjugate. Female,
athymic nude mice were transplanted with 2 × 106 C6 cells in a volume of
100 µ l. After 7 days, mice were treated with conjugate (10 µ g day–1
intraperitoneally) for a 2-week period. Tumour growth was followed by caliper
measurements. Each value is a mean of six animals with respective standard
errors.    = PBS control;   = VEGF121–DT385 conjugate-treated. The
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Figure 4 Immunohistochemical analysis of tumour tissues. Paraffin
embedded sections of tumour tissue were stained for von Willebrand’s factor
(factor VIII) and counterstained with haematoxylin. (A and B) Factor VIII
staining, (A) PBS control, (B) VEGF121–DT385 conjugate-treated tissue.
Arrows indicate factor VIII-positive vessels. * shows area of extravascular
staining of factor VIII corresponding to a thrombotic lesion. Tumour tissue
was also stained for TUNEL-positive cells to identify apoptotic activity,
(C–E) TUNEL assay, (C) PBS control tumour tissue, (D) VEGF121–DT385
conjugate-treated tumour tissue. Arrows indicate location of tumour vessels,
(E) apoptotic index as determined by counting the percentage of
TUNEL-positive pixels per image. Scale bar = 50 µ maddition, VEGF121 binds selectively to VEGFR-2 compared to
VEGFR-1. Both VEGFR-1 and VEGFR-2 have been found to be
up-regulated at the tumour site (Plate and Risau, 1995). Therefore,
targeting toxin polypeptides by VEGF165 could bind to VEGFR-1
and VEGFR-2 on tumour vessels as well as NP-1 on certain
normal tissues. In contrast, VEGFR121 will selectively bind and
deliver toxin molecules via VEGF-2 and bypasses toxin delivery
to NP-1-positive cells. In this context, it was interesting to note
that VEGF121–DT385 had a very similar cytotoxicity profile to
HUVECs when compared to the VEGF165–DT385 conjugate.
HUVEC cultures express VEGFR-1, VEGFR-2 as well as NP-1
(Soker et al, 1996; 1998). Furthermore, the administration of either
the VEGF165–DT385 or the VEGF121–DT385 conjugate resulted
in specific vascular damage at the tumour site. Normal vessels
were not affected by the treatment (Olson et al, 1997). Therefore,
it appears as if toxin delivery by VEGF molecules to endothelial
cells is preferentially targeted via VEGFR-2. The presence or
absence of exon 7 in the VEGF isoforms does not appear to change
the overall anti-angiogenic activity of the conjugate. However, it
may influence the toxicity profile of the construct. This is of
particular interest, since NP-1 is highly expressed on neuronal
cells. As a consequence, targeting toxins via VEGF165 may exert
some underlying neurotoxic effects.
For the differential effect of conjugate on tumour vasculature,
there are three possible explanations: proliferating endothelium,
such as tumour-associated vessels, are more sensitive to the conju-
gate than normal, quiescent endothelium; VEGF receptors are
highly expressed on tumour endothelium (Plate et al, 1993);
VEGF receptor accessibility in normal vessels might be limited
due to its abluminal distribution (Feng et al, 2000). However, at
the tumour site, conjugates can escape from the circulation due to
inherent leakiness of tumour vessels and bind to abluminal recep-
tors. Our present studies provide evidence for the first hypothesis;
VEGF121–DT385 conjugates selectively inhibited proliferating
endothelial cells when compared to confluent cultures. It is
possible that confluent cells have reduced numbers of VEGFRs.
However, a similar phenomenon has been previously observed
with an antibody–toxin conjugate against the transferrin receptor
on human corneal endothelium (HCE). Both receptor number and
affinity did not change between confluent vs proliferating cells
(Fulcher et al, 1988). Alternatively, conjugate internalization
and/or intracellular routing of the conjugate could be different in
proliferating vs quiescent cells. Rapid delivery of the internalized
toxin-constructs to lysosomes significantly reduces their cytotoxi-
city (Lappi, 1995). Therefore, differences in the functional status
of the VEGF receptors may contribute to the differential sensi-
tivity to the VEGF–toxin conjugate.
Lastly, we reported that inhibition of tumour angiogenesis by
the VEGF121–DT385 conjugate resulted in the localized apop-
totic death of tumour cells surrounding blood vessels. Although
the current treatment protocol produced significant inhibition of
tumour growth and temporary stabilization, it did not induce
regression. Therefore, a prolonged treatment regimen may be
desirable. Moreover, a recent report demonstrated that C6 gliomas
undergo robust angiogenesis at the tumour periphery around week
4 of solid tumour development (Holash et al, 1999). Based on
these results, a change in treatment schedule would be expected to
significantly improve the antitumour activity of the conjugate. On
the contrary, some tumour cells may still survive this vascular
targeting strategy by coopting existing host vessels, which
were not affected by the conjugate treatment. Under these
circumstances, complementary approaches such as chemotherapy
and radiation may have to be used in conjunction with anti-
angiogenic therapies to accomplish complete eradication of
tumours.
In summary, our results provide evidence that toxin delivery via
the VEGF121 isoform can efficiently target endothelial cells,
particularly proliferating or activated endothelial cells. In addition,
VEGF121–toxin conjugates effectively inhibited tumour growth
in vivo. The VEGF121 isoform might be a more suitable vascular
targeting moiety since it does not bind NP-1 receptors, which are
expressed in normal tissues. VEGF121 also preferentially binds
VEGFR-2. However, our in vitro and in vivo data suggest, that
both VEGF121 and VEGF165 might act in a similar mechanism on
endothelial cells. Therefore, VEGF–toxin conjugates might prefer-
entially target VEGFR-2 and do not require the binding to NP-1
receptors. Future experiments will focus on the potential difference
in toxicity profile using the two different VEGF isoforms.
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